Neuroimaging Studies of Reward Processing in Depression
Completed
Conditions studied: Major Depressive Disorder
In brief
This study investigates stress-related signaling of glutamate and dopamine within the reward-processing circuit in Major Depressive Disorder (MDD), and whether they can be used to predict depressive symptoms in the future. This will be achieved through various neuroimaging tools (MRS, fMRI, PET), behavioral tasks, and a naturalistic follow-up design.
Key facts
- Study ID
- NCT03026036
- Run by
- Mclean Hospital
- People needed
- 123
- Starts
- 2016-04-01
- Expected to finish
- 2021-03-01
- Last updated by the study team
- 2023-02-03
Who can join
Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.
You may not qualify if…
- Subjects with suicidal ideation where outpatient treatment is determined unsafe by the study clinician
- Pregnant women
- Failure to meet standard MRI or PET safety requirements
- Serious or unstable medical illness
- History of seizure disorder
- History or current diagnosis of organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, OCD, PTSD, mood congruent or mood incongruent psychotic features, substance dependence, substance abuse within the last 12 months (with the exception of cocaine or stimulant abuse, which will lead to automatic exclusion)
- Simple phobia, social anxiety disorder, and generalized anxiety disorder will be allowed only if secondary to MDD and only in the MDD group
- History of cocaine or stimulant use (e.g., amphetamine, cocaine, methamphetamine)
- History of use of dopaminergic drugs (including methylphenidate)
- Patients with a lifetime history of electroconvulsive therapy (ECT)
Where it is running
- David Crowley — Belmont, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.